Tetra Med Sciences sets up its R&D centre in Hyderabad
Hyderabad: Tetra Med Sciences, a subsidiary of US-based Tetra Global, started its R&D operations at Nacharam, Hyderabad. The company is engaged in the new molecule development and building a portfolio of molecules required in the coming five to 10 years. Tetra Med Sciences founded by Rama S Eyunni and Lathaa Subramanian with a vision to […]
Hyderabad: Tetra Med Sciences, a subsidiary of US-based Tetra Global, started its R&D operations at Nacharam, Hyderabad. The company is engaged in the new molecule development and building a portfolio of molecules required in the coming five to 10 years.
Tetra Med Sciences founded by Rama S Eyunni and Lathaa Subramanian with a vision to enhance access to affordable healthcare with new molecule development to help humanity to lead healthy lives. The initial focus will be on developing molecules with their intermediates for bulk drugs and going off-patent now and in coming 5 -10 years; and after getting drug licence – work on finished API doses also.
The company aims to work on bulk drugs and other domains; and plans to acquire its own production facility at the earliest but for now has signed a third party facility for immediate needs. The company is currently working on molecules for pharma and plans to roll out cost-competent and non-infringing intermediates. The team has expertise in the fields of drug discovery, medicinal chemistry besides aroma chemicals.
Speaking on the occasion, Sunita Eyunni, director, Tetra Med Sciences, said, “Covid-19 impacted global supply chains especially in the pharma sector given the huge dependence on active pharmaceutical ingredients (API) from China; molecule development and formulation of drugs became a huge challenge not just in India but globally as well.”
“As cost, quality & timely deliveries are critical components of the supply chain – Covid19 impact jeopardised the production schedule of pharma firms. Our new R&D Centre at Hyderabad, the pharma hub of India is an important step in our commitment to the Government of India’s Atmanirbhar vision,” she added.
Lathaa Subramanian, founder, Tetra Med Sciences added, “Recognising the impact of API supply chain shortage and cost competency of the pharma sector and encouraged by government support for women entrepreneurs; we decided to work in new molecules development starting with intermediates for API. Given the huge scientific talent pool at Hyderabad, knowledge base and competitive manpower advantage, we look forward to working with the pharma industry.”
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
Related News
